New paper by Dr. Jean-Philippe Theurillat Lab

news on 21 Sep , 2017
The publication in the renowned scientific journal Nature Medicine describes how the degradation of BET proteins are regulated by point mutations in the ubiquitin ligase adaptor protein SPOP and how this affects the sensitivity to BET protein inhibitors - a class of chromatin interacting small molecules that are currently in clinical development. Article: Opposing effects of cancer type-spec...
More

Dr. Giuseppina Carbone presented at the European Association of Urology in London

news on 18 May , 2017
Dr. Giuseppina Carbone presented at the European Association of Urology in London (EAU17,24-28 March,London) at the Thematic session on personalized medicine in prostate cancer. Knowledge of overexpressed oncogenes and the importance of the transcription factor ETS-related gene (ERG) and cytokines in relation to individualised therapy in prostate cancer, were examined today during the “Personal...
More

New study published in Oncotarget by Dr. Carbone group

news on 8 Oct , 2016
The study, conducted by Dr. Giuseppina Carbone and collaborators in Experimental Therapeutics and Prostate Cancer Biology, demonstrates that the transcription factor ESE3/EHF controls the IL-6/JAK/STAT3 axis and shows that targeting this pathway is beneficial in aggressive prostate tumors with reduced ESE3/EHF activity.
More